Genmab — April 2019

[Jazzz]

Stockbull.. der er vel ikke specielt lavt volumen.. 10% over det månedlige gennemsnit, 184.000 aktier handlet.

[Vitus]

Nordea blev jo sidenhen også klogere: OMX, har pr. den 15. marts meddelt, at alt handel på C25, S30 og H25 vil fra den 8. april være anonymt.

På grund af ovennævnte vil vi senere fjerne Handelsstatistikken for effekter på disse markeder.

[bibob]

God morgen. :-).

[transalp]

Go morgen:
)..

[Helge_LarsenPI-redaktør]

God morgen.

[Helge_LarsenPI-redaktør]

Her er den lange "forklaring" på det med anonymiseringen
https://newsclient.omxgroup.com/.../viewDisclosure.action...
... i en meddelelse fra Nasdaq selv, som man iøvrigt ikke kan finde noget sted hverken under Markedsmeddelelser eller i press center på deres hjemmeside.

[Helge_LarsenPI-redaktør]

Jeg prøver igen: https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=879726&lang=en&fbclid=IwAR09-39QNhbt9ucMGREwQZDyadPP42L0nXgSgL5g-fDz-_aHPeyOhHhjJgQ

[concillado]

...nogen kan så i følge dit link godt subscribe på visibility, som jeg læser det?

[polle1]

God morgen og god dag

[E_L]

Current status of autologous stem cell transplantation for multiple myeloma - Blood Cancer JournalBlood Cancer Journal

• https://www.nature.com/articles/s41408-019-0205-9?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bcj%2Frss%2Fcurrent+(Blood+Cancer+Journal)

[E_L]

this must be the maintenance study they announced last week, named AURIGA https://clinicaltrials.gov/ct2/show/NCT03901963?term=NCT03901963&rank=1

[E_L]

Some LYRA results posted on clinicaltrials https://clinicaltrials.gov/ct2/history/NCT02951819?A=18&B=19&C=merged

[iboge]

Hvorfor laver man ikke det omvendte forsøg: A Study of Daratumumab Plus Lenalidomide Versus Daratumumab Alone for at vise, at Lenalidomide ikke er nødvendig ?.

[E_L]

because they actually seem to work well together

[Tandfeen-2]

Grrr, så falder vi tilbage igen

[E_L]

JNJ is doubling the size in the BCMA CD3 DuoBody trial, as it adds SC arms.

[E_L]

"Participants will receive JNJ-64007957 subcutaneously (SC) starting at an IV dose and schedule that was deemed safe and cleared by the safety evaluation team (SET). "

[E_L]

sounds positive to me they are doing this and indicates they have not yet found major safety issues with IV and found a "safe dose"

[E_L]

i think they did something similar to this, earlier this year with the CD3 GPRC5D trial

[kkjoel]

A very good little piece of news: sc-arms on BCMAxCD3 study - tnx EL